Informationen:
Fehler:
ID
16992
Beschreibung
A Study of Mitomycin C, Irinotecan, and Cetuximab; ODM derived from: https://clinicaltrials.gov/show/NCT00271011
Link
https://clinicaltrials.gov/show/NCT00271011
Stichworte
Versionen (1)
- 18.08.16 18.08.16 -
Hochgeladen am
18. August 2016
DOI
Für eine Beantragung loggen Sie sich ein.
Lizenz
Creative Commons BY 4.0
Modell Kommentare :
Hier können Sie das Modell kommentieren. Über die Sprechblasen an den Itemgruppen und Items können Sie diese spezifisch kommentieren.
Itemgroup Kommentare für :
Item Kommentare für :
Um Formulare herunterzuladen müssen Sie angemeldet sein. Bitte loggen Sie sich ein oder registrieren Sie sich kostenlos.
Eligibility Colorectal Cancer NCT00271011
Eligibility Colorectal Cancer NCT00271011
- StudyEvent: Eligibility
Ähnliche Modelle
Eligibility Colorectal Cancer NCT00271011
- StudyEvent: Eligibility
Name
Typ
Description | Question | Decode (Coded Value)
Datentyp
Alias
diagnosis of colorectal cancer
Item
1. pathologic diagnosis of colorectal cancer.
boolean
C0011900 (UMLS CUI [1,1])
C0009402 (UMLS CUI [1,2])
C0009402 (UMLS CUI [1,2])
metastatic disease
Item
2. clinical and/or radiologic evidence of metastatic disease.
boolean
C0027627 (UMLS CUI [1])
previous treatment for metastatic disease
Item
3. one previous systemic treatment for metastatic disease.
boolean
C2114510 (UMLS CUI [1,1])
C0027627 (UMLS CUI [1,2])
C0027627 (UMLS CUI [1,2])
age
Item
4. age > 18.
boolean
C0001779 (UMLS CUI [1])
measurable lesion
Item
5. presence of at least one measurable lesion.
boolean
C1513041 (UMLS CUI [1])
neutrophil count, platelets, creatinine, bilirubin, transaminases
Item
6. adequate hematopoetic (absolute neutrophil count > 1500/mm3, platelet count > 100,000/mm3), renal (serum creatinine < 1.5 mg/dl), and hepatic function (bilirubin < 1.5 and transaminases < 5.0 x upper normal limit).
boolean
C0200633 (UMLS CUI [1])
C0005821 (UMLS CUI [2])
C0201976 (UMLS CUI [3])
C1278039 (UMLS CUI [4])
C0002594 (UMLS CUI [5])
C0005821 (UMLS CUI [2])
C0201976 (UMLS CUI [3])
C1278039 (UMLS CUI [4])
C0002594 (UMLS CUI [5])
ecog performance status
Item
7. ecog performance status 0-2.
boolean
C1520224 (UMLS CUI [1])
life expectancy
Item
8. life expectancy > 3 months.
boolean
C0023671 (UMLS CUI [1])
informed consent
Item
9. patients must be informed of the investigational nature of this study and provide written informed consent in accordance with the institutional and federal guidelines prior to the initiation of therapy.
boolean
C0021430 (UMLS CUI [1])
brain metastasis
Item
1. no recognized brain metastasis.
boolean
C0220650 (UMLS CUI [1])
mitomycin c or cetuximab
Item
2. no previous treatment with mitomycin c or cetuximab.
boolean
C0002475 (UMLS CUI [1])
C0995188 (UMLS CUI [2])
C0995188 (UMLS CUI [2])
comorbidity, malignant neoplasm
Item
3. no other systemic malignancy requiring treatment within the past one year.
boolean
C0009488 (UMLS CUI [1,1])
C0006826 (UMLS CUI [1,2])
C0006826 (UMLS CUI [1,2])
pregnancy, contraceptive methods
Item
4. pregnant or lactating women may not participate. women/men of reproductive potential must agree to use an effective contraceptive method.
boolean
C0032961 (UMLS CUI [1])
C0700589 (UMLS CUI [2])
C0700589 (UMLS CUI [2])
no other serious medical or psychiatric illness
Item
5. patients must have no other serious medical or psychiatric illness that would limit the ability of the patient to receive protocol therapy or provide informed consent.
boolean
C0009488 (UMLS CUI [1])
C0004936 (UMLS CUI [2])
C0004936 (UMLS CUI [2])